Literature DB >> 20453631

Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study.

Colette Smith, Caroline A Sabin, Jens D Lundgren, Rodolphe Thiebaut, Rainer Weber, Matthew Law, Antonella d'Arminio Monforte, Ole Kirk, Nina Friis-Moller, Andrew Phillips, Peter Reiss, Wafaa El Sadr, Christian Pradier, Signe W Worm.   

Abstract

OBJECTIVE: To investigate any emerging trends in causes of death amongst HIV-positive individuals in the current cART era, and to investigate the factors associated with each specific cause of death.
DESIGN: An observational multicentre cohort study.
METHODS: All HIV-positive individuals included in one of the cohorts in the Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study were included. The association between HIV-specific and non HIV-specific risk factors and death were studied using multivariable Poisson regression.
RESULTS: We observed 2482 deaths in 180,176 person-years (PY) on 33,308 individuals [rate/1000 PY = 13.8 (95% CI 13.2-14.3)]. Primary causes of death were: AIDS (n = 743; rate/1000 PY = 4.12), liver-related (341; 1.89), CVD-related (289; 1.60), non-AIDS malignancy (286; 1.59). The overall rate of death fell from 16.9 in 1999/2000 to 9.6/ 1000 PY in 2007/2008. Smoking was associated with CVD and non-AIDS cancers, HBV and HCV co-infection with liver-related deaths, and hypertension with liver-related and CVD deaths. Diabetes was a risk factor for all specific causes of death except non-AIDS cancers, and higher current HIV RNA for AIDS-related deaths. Lower CD4 cell counts were associated with a higher risk of death from all specific causes of death.
CONCLUSION: Multiple potentially modifiable traditional and HIV-specific risk factors for death of HIV-infected persons were identified. The maximum reduction in mortality in HIV-infected populations will require that each of these factors be appropriately addressed. No trends in terms of emerging causes of unexpected deaths were observed, although monitoring will continue.

Entities:  

Mesh:

Year:  2010        PMID: 20453631     DOI: 10.1097/QAD.0b013e32833a0918

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  197 in total

1.  Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters.

Authors:  Helen M Chun; Mollie P Roediger; Katherine Huppler Hullsiek; Chloe L Thio; Brian K Agan; William P Bradley; Sheila A Peel; Linda L Jagodzinski; Amy C Weintrob; Anuradha Ganesan; Glenn Wortmann; Nancy F Crum-Cianflone; Jason D Maguire; Michael L Landrum
Journal:  J Infect Dis       Date:  2011-12-05       Impact factor: 5.226

Review 2.  Renal disease in HIV-infected individuals.

Authors:  John Phair; Frank Palella
Journal:  Curr Opin HIV AIDS       Date:  2011-07       Impact factor: 4.283

Review 3.  When to start ART in the setting of acute AIDS-related opportunistic infections: the time is now!

Authors:  Philip M Grant; Andrew R Zolopa
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

4.  Hepatitis C Direct Acting Antiviral Therapies in a New York City HIV/AIDS Special Needs Plan: Uptake and Barriers.

Authors:  Mark H Kuniholm; Terry Leach; Joseph Lunievicz; Noemí Olivo; Kathryn Anastos; Yvette Vazquez; Mark Brennan-Ing; Stephen E Karpiak; Oladipo Alao; Denis Nash; Jerome Ernst
Journal:  AIDS Patient Care STDS       Date:  2015-12       Impact factor: 5.078

5.  Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-coinfected veterans.

Authors:  Jeffrey P Anderson; Eric J Tchetgen Tchetgen; Vincent Lo Re; Janet P Tate; Paige L Williams; George R Seage; C Robert Horsburgh; Joseph K Lim; Matthew Bidwell Goetz; David Rimland; Maria C Rodriguez-Barradas; Adeel A Butt; Marina B Klein; Amy C Justice
Journal:  Clin Infect Dis       Date:  2013-11-27       Impact factor: 9.079

6.  Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men.

Authors:  Markella V Zanni; Suhny Abbara; Janet Lo; Bryan Wai; David Hark; Eleni Marmarelis; Steven K Grinspoon
Journal:  AIDS       Date:  2013-05-15       Impact factor: 4.177

7.  Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study.

Authors:  Helen Kovari; Caroline A Sabin; Bruno Ledergerber; Lene Ryom; Signe W Worm; Colette Smith; Andrew Phillips; Peter Reiss; Eric Fontas; Kathy Petoumenos; Stéphane De Wit; Philippe Morlat; Jens D Lundgren; Rainer Weber
Journal:  Clin Infect Dis       Date:  2012-10-22       Impact factor: 9.079

Review 8.  Enhancing our understanding of current therapies for hepatitis C virus (HCV).

Authors:  Neliswa A Gogela; Ming V Lin; Jessica L Wisocky; Raymond T Chung
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

9.  Hepatitis C Virus Treatment in HIV-Coinfected Patients: No Longer Different From Monoinfection Treatment.

Authors:  Bevin Hearn; David Delbello; Joseph Lawler; Michel Ng; Alyson Harty; Douglas T Dieterich
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-11

10.  Hepatitis B Virus-HIV Coinfection: Forgotten but Not Gone.

Authors:  Narayan Dharel; Richard K Sterling
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.